AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate CancerBusiness Wire • 12/15/22
Merck, Moderna say mRNA vaccine and Keytruda lowers the risk of death in melanoma patientsMarket Watch • 12/13/22
Why Merck's $250 Million Investment In Moderna May Have Just Paid OffInvestors Business Daily • 12/13/22
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 TrialAccesswire • 12/13/22
Merck Global Health Innovation Fund and P74 Ventures Make Strategic Investment in TransVoyant for Intelligent, ‘Self Aware' Supply Chain PlatformBusiness Wire • 12/13/22
MDA Breakout Stocks Week 50 - December 2022: Short-Term Picks To Give You An EdgeSeeking Alpha • 12/11/22
Early Q4 Earnings Results and Analyst Reports for Merck, Bristol-Myers & DeereZacks Investment Research • 12/09/22
Is Merck Stock A Buy After Surging To A Fresh High On Its Imago Buyout Plans?Investors Business Daily • 12/06/22